Blue Box sensors: Ireland's newest pharmaceutical devices company by Lowry, John P. & Scanlan, John
Earlier this year Ireland’s newest pharmaceutical 
devices company, Blue Box Sensors was spun 
out by NUI Maynooth. Claire O’Connell spoke to 
Prof John Lowry, the Scientist who developed the 
sensor technology and Dr John Scanlan, Director 
of Commercialisation at NUI Maynooth to uncover 
the story behind launching the company. ‘
‘When a scientist makes an important discovery, the natural 
instinct is to shout it from the rooftops. Which in scientific 
circles means publishing papers in esteemed and peer-
reviewed journals. But for several years, Prof John Lowry, head 
of NUI Maynooth’s chemistry department, has had to hold off 
on publishing in journals or presenting at conferences, despite 
developing an implantable brain sensor that can boost our 
understanding of brain behaviour and help develop effective 
dr ugs against devastating neurological conditions. 
Why the silence? To protect the intellectual property 
underlying the sensors so the approach could be 
commercialised. Now his patience has paid off. This summer 
NUI Maynooth spun out BlueBox Sensors Ltd to manufacture 
devices that can track levels of chemicals in the brain in real 
time over the course of weeks or even months. The sensors 
offer fresh insight into the workings of the brain and stand to 
improve preclinical research and drug discovery for a range of 
diseases including Alzheimer’s, Parkinson’s  
and Schizophrenia.
Prof Lowry started developing the sensor platform for his 
doctoral research in the 1990s. ‘I started using electrodes to 
investigate and study the brain. It was an exciting time - this 
was a new technology and it offered huge potential,’ he recalls. 
‘My remit was to develop an electrode that would measure 
glucose in the brain - glucose being the main energy  
substrate - and by the end of my PhD I had a device that  
had passed all the test criteria in-vitro. So on the bench we 
were able to show it had a high sensitivity for glucose.’ 
Lowry continued to develop the sensor technology,  
moving to Oxford to validate measurements in animal 
models and tweaking the electrode surfaces to measure a 
range of key targets including oxygen, neurotransmitters 
(chemicals that allow brain cells to communicate) and 
by-products of brain metabolism. ‘Over the last few years 
the focus has been on designing the chemistry of the surface 
of the electrode, to give selectivity for the molecule to be 
measured,’ he explains. ‘And validating the approach – a lot of 
blood sweat and tears goes into that.’
Lowry was using the sensors to unpick mechanisms behind 
energy metabolism in the brain when he took the chair of 
chemistry at NUI Maynooth in 2006, and the sensors caught 
the eye of the Director of Commercialisation, Dr John 
Scanlan. ‘He was on the prowl) to see what researchers were 
doing and what might have commercial potential,’ recalls 
Lowry, who had already been building contacts and earning a 
solid reputation with pharmaceutical companies such as Eli 
Lilly and Solvay Pharmaceuticals.  
Orders were coming in from industry for the sensors,  
and Lowry and his team, including Laboratory Manager  
Maryanne Dalton, started to struggle to meet demand.  
So NUI Maynooth decided to spin out a company, and  
filed five patents on the technology to protect it. ‘In terms  
of starting a company on something like this, there are 
several challenges and one is always the intellectual 
property,’ explains Scanlan. 
 
‘John is heavily funded by Science Foundation Ireland, and, 
with that, comes pressure to publish. But if the work is 
published before being patented, it’s out in the open and 
there’s nothing left to commercialise.’
Scanlan commends Lowry on holding back publications 
within the context of a longer-term commercial goal. ‘It’s 
a major challenge for an academic. They get hammered if 
they hold back on publising to develop clean IP (intellectual 
property). We need someone like John, who believes in the 
process and is willing to hold back publishing in the medium 
term because the work is too valuable. We know he is 
excellent in science but for someone to be brave enough 
to stand up and say I believe in the process takes a lot of 
courage.’ With the commercial potential of the validated 
sensor platform technology becoming apparent, members 
of Lowry’s team secured funding from Enterprise Ireland to 
move the sensors closer to market. 
Building close contacts with pharmaceutical companies 
– the eventual customer base – provided an important 
compass for the enterprise, and having clean, patented IP, 
strengthened the opportunity further, notes Scanlan. ‘We like 
to have market-informed research,’ he says. ‘In this instance 
we asked companies what was of interest to them, they 
wanted some way of measuring glucose and dopamine in 
real time when the animal is doing tasks. John [Lowry] closed 
the lab doors and figured out how to do it and came out and 
with the answer. It means we have clean IP and clean IP is 
essential, but it is also market informed so he knows that if 
he develops this, a pharmaceutical company will buy it.’
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Meanwhile NUI Maynooth designed an agile company 
structure to dovetail with the scientific expertise, bringing in 
a management team with experience in the field. ‘Part of the 
programme that has been developed here, which is relatively 
unique to NUI Maynooth, is that the academics don’t start 
the companies,’ explains Dr Scanlan. Instead they wait until 
they have clean IP and a sense of the customer base before 
headhunting managers with exemplary track records of starting 
new companies.  ‘The management team we have pulled into 
this have been involved in selling the technologies that this 
technology will replace,’ comments Dr Scanlan. ‘They are close 
to the market, close to the customers and know the market 
demand.’
Scanlan believes the company will grow organically, working 
towards building up a reputation within the industry and 
regulators with the aim of replacing the standard practice of 
microdialysis, which is limited by not being real-time and by  
not being as sensitive.
Their eyes are also on a powerful stamp of approval,  
according to Scanlan. ‘The ultimate goal would be to have it  
FDA approved so that the FDA request data from Blue Box 
sensors, in the knowledge that the sensors provide the best 
data,’ he says.
While it has been a long wait to publish for Lowry, the payoff 
is seeing the flood of articles now going into peer-reviewed 
journals, knowing it will make a difference. 
‘For me personally, through interacting with industry, I will 
probably deliver something that will be useful for patients, 
whether it’s for psychosis or neurodegeneration, a lot quicker 
and something real than if I just stayed plugging away with 
State funding,’ he says. ‘These guys know how to do it, and 
academics can learn a huge amount from industry people.’
– Supported by Enterprise Ireland
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